IO Biotech announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company?s lead cancer vaccine candidate currently in a pivotal Phase 3 trial. Ms. Shamsaei joins the company?s executive team, reporting to IO Biotech CEO Mai-Britt Zocca, Ph.D., and is based in the United States. Dr. Shamsaei is an accomplished executive with over 25 years of experience in the pharmaceutical and biotechnology industry developing commercial and portfolio strategies in multiple therapeutic areas.

Most recently, she served as Vice President, Head of Commercial at Allogene Therapeutics. Prior to this role, she served in leadership roles at Five Prime Therapeutics (acquired by Amgen), Genentech, Jazz Pharmaceuticals and SUGEN/Pharmacia (acquired by Pfizer). Dr. Shamsaei holds a Doctorate in Pharmacy from the University of California San Francisco and a Bachelor of Arts in Chemistry from the University of Colorado.